...
机译:他莫昔芬治疗后具有高细胞质Src激酶表达的ER阳性乳腺癌患者的疾病特异性生存期缩短
Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Western Infirmary, McGregor Building, Dumbarton Road, Glasgow, G11 6NT, UK;
Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Western Infirmary, McGregor Building, Dumbarton Road, Glasgow, G11 6NT, UK;
Department of Surgery, Crosshouse Hospital, Kilmarnock Road, Kilmarnock, KA2 0BE, UK;
Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Western Infirmary, McGregor Building, Dumbarton Road, Glasgow, G11 6NT, UK;
Src kinase; ER-positive breast cancer; Disease-specific survival; Immunohistochemistry; Tamoxifen;
机译:他莫昔芬治疗后具有高细胞质Src激酶表达的ER阳性乳腺癌患者的疾病特异性生存期较短
机译:一线他莫昔芬治疗复发性疾病的ER阳性乳腺癌患者中,GATA3 mRNA的表达而非突变与更长的无进展生存相关
机译:是否与酪氨酸530上Src激酶的磷酸化和去磷酸化以及乳腺癌患者疾病特异性生存有关
机译:临床信息和基因表达的集成模型可预测乳腺癌患者的存活率
机译:通过Src激酶途径,微量营养元素硒和新型他莫昔芬调节的生物标记物对乳腺癌和子宫内膜癌中雌激素受体信号的调节。
机译:是否与酪氨酸530上Src激酶的磷酸化和去磷酸化以及乳腺癌患者疾病特异性生存有关
机译:一线他莫昔芬治疗复发性疾病的ER阳性乳腺癌患者中,GATA3 mRNA的表达而非突变与更长的无进展生存相关